Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
DG Science et Thérapies from Jette, company number BE1017196834, closed financial year 2025 with a result of € 9,394 after tax. For that financial year DG Science et Thérapies recorded a gross margin of € 27,673 and equity of € 28,788. Compared with financial year 2024, the result moved from € 18,323 to € 9,394. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 28,788
▲ 48% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,394
▼ 49% vs 2024
Profit after tax over the fiscal year.
€ 19,150
▲ € 18,080 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 27,718.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 933
▼ 50% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 17,399
€ 4,299 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 9,654
▲ € 8,034 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,089
▲ 57% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 36,773 | € 27,673 | ▼ 25% |
| Profit after taxes | € 18,323 | € 9,394 | ▼ 49% |
| Equity | € 19,393 | € 28,788 | ▲ 48% |
| Total debts | € 27,476 | € 52,309 | ▲ 90% |
| Cash | € 1,070 | € 19,150 | ▲ € 18,080 |
| Retained profit | € 18,323 | € 27,718 | ▲ 51% |
| Bank debt | € 0 | € 17,399 | |
| Balance sheet total | € 46,869 | € 81,097 | ▲ 73% |
Key figures of DG Science et Thérapies, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DG Science et Thérapies?
What happened at DG Science et Thérapies in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 9,394 (▼ 49% vs 2024). filed late Source: NBB ↗
- New establishment in Boortmeerbeek. KBO
- New establishment in Jette. KBO
- Eric De Gunsch became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 18,323 profit in 2024 to € 9,394 profit in 2025.
Paid € 9,089 in corporate taxes since 2024.
Best year ever: 2024, with € 18,323 profit.
A new publication or filing at DG Science et Thérapies? We notify you, reason included.
Follow DG Science et ThérapiesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DG Science et Thérapies is Eric De Gunsch.
Directors
According to the 2025 annual accounts
Eric De Gunsch
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Jaak Pieter Ballingslaan 17
1090 Jette
Rijkenhoekstraat 66
3191 Boortmeerbeek
Active since 11 December 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1017.196.834
- VAT number
- BE 1017.196.834
- Registered office
- Jaak Pieter Ballingslaan 17, 1090 Jette
- Names & denominations
- DG Science et Thérapies
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 December 2024
- Peppol
- Not registered